ZK283197 for Treatment of Vasomotor Symptoms
- Conditions
- Vasomotor System
- Interventions
- Registration Number
- NCT00537836
- Lead Sponsor
- Bayer
- Brief Summary
The primary goal of the planned study is to investigate the efficacy and safety of ZK 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes. In order to be able to assess the efficacy of the test substance, this is compared with the efficacy of 1 mg Estradiol and placebo. The comparator Estradiol is a certified hormone preparation, which is already used for the treatment of hot flushes as standard treatment. After passing the screening, volunteers will start with a run-in phase followed by a 8 weeks treatment and a follow-up phase. 112 postmenopausal women with hot flushes and without relevant prior diseases will participate in three European countries (2 study sites in Germany, 1 study site in Great Britain and 1 study site in The Netherlands) in this study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 116
- Women with at least 35 moderate to severe hot flushes in seven consecutive days
- Body mass index (BMI) : 20 - 30 kg/m² (inclusive)
- Postmenopausal status
- Contraindication for use for hormonal therapy
- Prior hysterectomy
- Hormonal therapy or intrauterine hormone releasing device within 4 weeks prior to study entry or any long-acting injectable or implant up to 6 months prior to study entry
- Repeated intake of medications affecting study aim
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ZK 283197, 3 mg BAY 86-5310 (ZK 283197) Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks Matching placebo Placebo Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks ZK 283197, 2 mg BAY 86-5310 (ZK 283197) Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks 17ß-estradiol 17ß-estradiol Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
- Primary Outcome Measures
Name Time Method Relative change in frequency of moderate to severe hot flushes per week between baseline and Week 8 of the treatment phase Between baseline and Week 8 of the treatment phase
- Secondary Outcome Measures
Name Time Method Number of participants with adverse events From Week 1 of treatment until end of Follow-up period (approximately 12 weeks) Exposure-response relationship At week 8 A generalized linear model was applied to explore the dependence of the number of hot flushes in Week 8 to (i) the dose of ZK 283197, (ii) the AUC of ZK 283197, (iii) the maximum concentration Cmax of ZK 283197 and (iv) the average concentration Cave of ZK 283197
Change from baseline to all treatment weeks in frequency and severity of moderate to severe hot flushes From baseline up to 8 weeks Change from baseline to all treatment weeks in severity and frequency of all hot flushes From baseline up to 8 weeks Trough levels at every visit Before 1st administration and at Week 1, 2, 4, 6 and 8 AUC(0-24h) Pre-dose and up to 24 h post-dose (measured between Week 4-8) Area under the curve from administration to 24 h after administration
Cmax Pre-dose and up to 24 h post-dose (measured between Week 4-8) Maximum serum concentration
tmax Pre-dose and up to 24 h post-dose (measured between Week 4-8) Time to reach maximum drug concentration
Cmin Pre-dose and up to 24 h post-dose (measured between Week 4-8) Minimum serum concentration
Cave Pre-dose and up to 24 h post-dose (measured between Week 4-8) Average serum concentration
Vaginal cytology Between baseline and Week 8 The epithelial maturation index/value and the karyopycnotic index were assessed
Endometrial thickness Fom baseline to Week 8 Transvaginal ultrasound was performed to demonstrate the absence of relevant endometrium growth
Endometrial histology Between baseline and Week 8